DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e4d0ba/latvia_pharmaceuti) has announced the addition of the "Latvia Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
Business Monitor International's Latvia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Latvia's pharmaceuticals and healthcare industry.
BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for innovative medicines. However, the performance of the pharmaceutical market remains indelibly tied to the country's macroeconomic environment. Having endured a three-year depression, the economy is finally set to return to positive growth in 2011. However, the road back to prosperity will be long, with private consumption still lagging behind the country's broader economic recovery, threatening the return of the predominantly out-of-pocket driven pharmaceutical market.
In February 2011, the Latvian Ministry of Health and the country's Health Economics Centre launched an information campaign to raise awareness the affordability and effectiveness of genetic medicines.
As stated by the Latvian State Agency of Medicines (SAM), a reduced VAT rate was applied to medical devices for individual use as of June 2011. These include single-use medical devices that are disposed of after use (such as syringes, gloves, catheters), custom-made medical devices (such as spectacles, prosthetics) and self-care medical devices (such as wheelchairs, functional beds, glucose monitors, respiratory monitors).
The key topics covered by "Latvia Pharmaceuticals and Healthcare Report Q4 2011" are:
- SWOT Analysis
- Pharmaceutical Business Environment Ratings
- Market Summary
- Regulatory Regime
- Industry Developments
- Industry Forecast Scenario
- Key Risks To BMI's Forecast Scenario
- Competitive Landscape
- Company Monitor
- Country Snapshot: Latvia Demographic Data
- Pharmaceutical And Healthcare Glossary
Companies Mentioned:
- Grindeks (includes Tallinn Pharmaceutical Plant)
- Olainfarm
- Pfizer
- GlaxoSmithKline
- Sanofi-Aventis
- Novartis
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/e4d0ba/latvia_pharmaceuti